{
  "ticker": "ABT",
  "cik": "0000001800",
  "company_name": "ABBOTT LABORATORIES",
  "filing_date": "2025-02-21",
  "item1_summary": " Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products . Products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets . Certain products are co-marketed or co-promoted with, or licensed from, other companies .\n The term “Abbott” refers to Abbott Laboratories, an Illinois corporation, or Abbott Laboratories and its consolidated subsidiaries, as the context requires . The Established Pharmaceutical Products segment directs its primary marketing efforts toward building strong brands with key stakeholders, including consumers, pharmacists, physicians, and other healthcare providers .\n Abbott's Diagnostic Products segment includes systems used for screening and diagnosis for cancer, cardiac and metabolic disorders, drugs of abuse, thyroid function, fertility, and fertility . Products are generally marketed and sold directly to blood banks, hospitals, commercial laboratories, clinics, physicians’ offices, retailers, and retailers, government agencies, alternate care testing sites .\n Diagnostic Products segment includes molecular point-of-care testing for HIV, HIV, hepatitis, and tropical diseases such as malaria and dengue fever . Nutritional products include a broad line of pediatric and adult nutritional products . Diagnostic products are subject to competition in technological innovation, price, convenience of use, service, instrument warranty provisions, product performance, laboratory efficiency, and product potential for overall cost-effectiveness and productivity gains .\n Competition for nutritional products in the segment is generally from other diversified consumer and healthcare manufacturers . Competitive factors include consumer advertising, formulation, packaging, scientific innovation, price, retail distribution, and availability of product forms . Primary marketing efforts are directed toward consumers or physicians or other healthcare professionals . The introduction of new products by competitors, changes in medical practices and procedures can result in product obsolescence .\n Medical devices are manufactured, marketed and sold worldwide . Products include a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products . Medical devices include pacemaker systems, cardiac mapping systems, implantable cardioverter defibrillators and implantable cardiac monitors .\n Aortic valve and mitral valve replacement devices are among the products developed on the Multi-Link Vision® platform . HeartMate®® left ventricular assist device family; the CardioMEMS®®® HF System pulmonary artery sensor, a heart failure monitoring system; and patient self-testing products and services . The OPTIS®® integrated systems with Ultreon® 1.0 and 2.0 Software, compatible with the Dragonfly OPTIS™™ and OpStar®® optic imaging catheters .\n Abbott’s products are subject to competition in technological innovation, price, convenience of use, service, product performance, product potential for overall cost-effectiveness and productivity gains . Some products in this segment can be subject to rapid product obsolescence or regulatory changes . There have been no recent significant availability problems or supply shortages for raw materials or supplies .\n There are no significant seasonal aspects to Abbott’s business . Abbott has no single customer that, if the customer was lost, would have a material adverse effect on Abbott . No material portion of the business is subject to renegotiation of profits or termination of contracts at the election of a government . No single patent, license, or trademark is material in relation to Abbott's business as a whole .\n As of December 31, 2024, Abbott employed approximately 114,000 people, 69% of whom were employed outside of the U.S. Women represented 47% of the workforce, and 43% of its global workforce . The company is committed to improving health in more than 160 countries . It has an integrated global talent management process that is designed to identify and assess talent across the world .\n Abbott's diversity, equity, and inclusion report provides an update on the plans, strategies, and actions undertaken to ensure that Abbott continues to attract, retain, and develop the best talent from the more than 160 countries in which it does business . Abbott ties executive compensation to human capital management to sustain an inclusive culture .\n Abbott is committed to building, retaining, and motivating a diverse talent pipeline that can meet the current and future needs of its businesses . The health, safety and wellness of its employees is an Abbott priority embedded at every level of its business . Abbott’s global wellness programs are designed to meet the unique needs of employees across businesses and geographies .\n Development, manufacture, marketing, sale, promotion, and distribution of Abbott’s products are subject to comprehensive government regulation by the U.S. Food and Drug Administration (FDA) and similar national and international regulatory agencies . Abbott also has procedures and processes focused on ensuring employees receive equitable compensation, regardless of race or gender or other personal characteristics .\n Abbott’s laboratory facilities, home monitoring services, and durable medical equipment suppliers, are subject to additional laws and regulations applicable to healthcare providers and suppliers that submit claims for reimbursement or payment to third-party payors . Governmental agencies can also invalidate intellectual property rights . Failure to comply can delay the release of a new product or result  investments, or limit the import of raw materials and finished products .\n Abbott’s business can also be affected by ongoing studies of the utilization, safety, efficacy, and outcomes of healthcare products and their components . Compliance with the laws and regulations governing laboratories and testing services requires specialized expertise . Failure to comply with these regulatory requirements can result in sanctions, including suspension, revocation, or limitation of laboratory certification . Abbott expects that insurers and providers will continue attempts to reduce the cost of health care .\n Many countries control the price of healthcare products directly or indirectly, through reimbursement, payment, pricing, or coverage limitations . Budgetary pressures on healthcare payors may also heighten the scope and severity of pricing pressures on Abbott’s products for the foreseeable future . In the United States, the federal government regularly evaluates reimbursement for medical devices, diagnostics, supplies, and other products .\n The Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act . Failure to report appropriate data may result in civil or criminal fines and/or penalties . The European Union, China, various other countries, and various U.S. states have enacted or are considering enacting data protection laws .\n Abbott expects debate to continue at all government levels worldwide over the manufacture, quality assurance requirements, marketing authorization processes, post-market surveillance requirements, availability, method of delivery, and payment for healthcare products and services . Failure to comply with data privacy and security laws and regulations can result in business disruption and enforcement actions, which could include civil or criminal penalties .\n Copies of Abbott’s Annual Report on Form 10-K, Quarterly Reports on Form . Reports are available, free of charge, at www.abbottinvestor.com . Corporate governance guidelines, outline of directorship qualifications, code of business conduct are all available on Abbott's investor relations website . Abbott's corporate governance guidelines and the charters of its audit committee, compensation committee, nominations and governance committee are all ."
}